poisar

Stocks · News reference

Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer

Vandana Singh

European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ALPMFALPMYMRKPFE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

    The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

    ALNYIONSSRPTBIIBNVS
  5. Geoffrey Seiler

    2 High-Yield Dividend Stocks to Buy and 1 to Avoid

    The article recommends buying Energy Transfer and Verizon as high-yield dividend stocks, while advising investors to avoid Pfizer. Energy Transfer benefits from AI data center demand for natural gas with a 6.4% yield and strong growth prospects. Verizon offers a 5.8% yield with improving subscriber metrics and fiber growth opportunities. Pfizer is flagged as risky due to unsustainable dividend payouts exceeding free cash flow, high debt from the Seagen acquisition, and an upcoming patent cliff on blockbuster drugs.

    ETETPIVZPFE
  6. Todd Shriber

    If a Recession Is Coming, History Says This 1 No-Brainer ETF Is the Smartest Buy Right Now

    With bond market signals suggesting potential recession risks, the Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) is positioned as a defensive investment option. The ETF gained 0.6% in 2022 when the S&P 500 fell 18.2%, offering exposure to recession-resilient sectors like consumer staples and healthcare while avoiding volatile tech stocks. Its 4.82% dividend yield and low volatility make it attractive for risk-averse investors seeking portfolio protection.

    SPHDVZPFEGIS